Z-LEHD-fmk Options
The main end issue was the protection and tolerability of sifalimumab. Treatment-emergent adverse functions (AEs) and critical AEs (SAEs) as well as their severity, final result, and any connection to the review medication had been recorded via the investigator all through the analyze. AEs had been considered prone to be relevant to research medica